MARKET

VERU

VERU

Veru
NASDAQ
5.31
-0.40
-7.07%
Opening 12:11 02/07 EST
OPEN
5.78
PREV CLOSE
5.71
HIGH
5.78
LOW
5.25
VOLUME
759.10K
TURNOVER
2.04M
52 WEEK HIGH
24.55
52 WEEK LOW
4.340
MARKET CAP
427.82M
P/E (TTM)
-5.0794
1D
5D
1M
3M
1Y
5Y
Veru Has Received A Notice Of Allowance For Its U.S. Patent Application 17/222,835 Titled "Methods Of Treating Coronavirus".
Benzinga · 01/12 16:03
Why Is VERU Stock Up 8% Today?
Investor Place · 01/10 20:20
BRIEF-Veru Announces Appointment Of Dr. David Ho As Chairman Of Its Infectious Disease Scientific Advisory Board
Reuters · 01/10 13:46
Jim Cramer Calls This Small-Cap Energy Stock The 'Best Natural Gas Company And A Great Oil Company'
Benzinga · 01/09 13:32
Veru Earnings Perspective: Return On Capital Employed
Benzinga · 12/30/2022 14:45
Veru Inc. (NASDAQ:VERU) Q4 2022 Earnings Call Transcript
Veru Inc. (NASDAQ:VERU) Q4 2022 Earnings Call Transcript December 5, 2022 Veru Inc. misses on earnings expectations. Reported EPS is $-0.51 EPS, expectations were $-0.3. Operator: Good morning ladies and gentlemen, and welcome to Veru Inc.’s Investor Confe...
Insider Monkey · 12/08/2022 18:59
Veru Full Year 2022 Earnings: Misses Expectations
Veru ( NASDAQ:VERU ) Full Year 2022 Results Key Financial Results Revenue: US$39.4m (down 36% from FY 2021). Net loss...
Simply Wall St. · 12/07/2022 13:15
HC Wainwright & Co. Maintains Buy on Veru, Lowers Price Target to $18
Benzinga · 12/07/2022 11:28
More
About VERU
Veru Inc. is an oncology biopharmaceutical company. The Company is focused on developing medicines for the management of breast and prostate cancers. The Company's FC2 segment consists of its commercial product, FC2. The Pharmaceuticals segment includes activities related to multiple drug products under clinical development and ENTADFI, a treatment for benign prostatic hyperplasia. It has a commercial Sexual Health Division, which includes two products, such as ENTADFI, a treatment for benign prostatic hyperplasia (BPH), and the FC2 Female Condom (Internal Condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.

Webull offers kinds of Veru Inc stock information, including NASDAQ:VERU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VERU stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VERU stock methods without spending real money on the virtual paper trading platform.